Ginkgo Bioworks announced on August 29, 2025, the proposed settlement of shareholder derivative actions pending in federal and Delaware Chancery courts. As part of the settlement, the Individual Defendants' Insurers will pay Ginkgo the sum of $4.125 million.
In addition to the cash payment, Ginkgo will terminate a certain contract and its Board will adopt, implement, and maintain comprehensive corporate governance, oversight, and internal controls reforms for a period of not less than three years. These reforms are intended to provide additional value to the company and its stockholders.
The company's Board, including its independent, non-defendant directors, determined that the settlement confers a substantial benefit upon Ginkgo and its stockholders and is fair, adequate, and reasonable. This resolution addresses the claims asserted in the derivative actions and removes legal uncertainty.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.